ArticleJournal of cachexia, sarcopenia and muscle2019
Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa.
Article in Journal of cachexia, sarcopenia and muscle, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Gene Ontology (GO)-Driven Inference of Candidate Proteomic Markers Associated with Muscle Atrophy Conditions.Molecules (Basel, Switzerland) · 2022Pooled it
- Clinical efficacy and safety evaluation of Buzhongyiqi pills on appetite improvement in patients with colorectal cancer receiving chemotherapy: a pilot randomized cross-over clinical trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2024Trial
- Effects of auricular acupuncture on appetite in patients with advanced cancer: a pilot randomized controlled trial.Annals of palliative medicine · 2020Trial
- Circulating granulocyte colony-stimulating factor as a sex-unbiased global marker of lung and colorectal cancer cachexia pre-clinical models.Experimental physiology · 2026Article
- Systemic Inflammatory Biomarkers and Cancer-Associated Cachexia: A Narrative Review.Current oncology (Toronto, Ont.) · 2026Review
- The Association Between Gut Microbiome and Cachexia in Colorectal Cancer: A Systematic Review.Cancers · 2026Review
- Multi-organ transcriptome profiling in an isogenic cachexia-inducing xenograft model to dissect host responses across heart, liver, kidney, and muscle.Human cell · 2026Article
- The Eubacterium Rectale Derived Extracellular Vesicles Alleviate Cancer Cachexia Induced Lipolysis by Inhibiting Macrophage Polarization.Journal of extracellular vesicles · 2026Article
- Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Higher abundance of micro- and nanoplastics in inflammatory tissues from patients with intestinal erosion.Frontiers in medicine · 2026Article
- The Monocrotaline Model of Hypertension Leads to Cachexia in Male but Not Female Mice.Journal of cachexia, sarcopenia and muscle · 2025Article
- Pharmacokinetic Implications of Pathophysiological Changes in Cachexia Syndrome: A Scoping Review.European journal of drug metabolism and pharmacokinetics · 2025Article
- Physical Activity, Exerkines, and Their Role in Cancer Cachexia.International journal of molecular sciences · 2025Review
- Bridging the tumor microenvironment: the pivotal role of cancer-associated fibroblasts in tumor cachexia development.Molecular cancer · 2025Review
- Single-cell technology reveals the crosstalk between tumor cells and immune cells: driving immune signal transduction and inflammation-mediated cardiac dysfunction in the tumor microenvironment of colorectal cancer.Frontiers in immunology · 2025Article
- Involvement of the gut microbiota in cancer cachexia.American journal of physiology. Cell physiology · 2024Review
- IL-6 promotes tumor growth through immune evasion but is dispensable for cachexia.EMBO reports · 2024Article
- Immunoregulation in cancer-associated cachexia.Journal of advanced research · 2024Review
- Advances in IL-7 Research on Tumour Therapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Unveiling the role of interleukin-6 in pancreatic cancer occurrence and progression.Frontiers in endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundCachexia is a multifactorial and multiorgan syndrome associated with cancer and other chronic diseases and characterized by severe involuntary body weight loss, disrupted metabolism, inflammation, anorexia, fatigue, and diminished quality of life. This syndrome affects around 50% of patients with colon cancer and is directly responsible for the death of at least 20% of all cancer patients. Systemic inflammation has been recently proposed to underline most of cachexia-related symptoms. Nevertheless, the exact mechanisms leading to the initiation of systemic inflammation have not yet been unveiled, as patients bearing the same tumour and disease stage may or may not present cachexia. We hypothesize a role for gut barrier disruption, which may elicit persistent immune activation in the host. To address this hypothesis, we analysed the healthy colon tissue, adjacent to the tumour.
methodsBlood and rectosigmoid colon samples (20 cm distal to tumour margin) obtained during surgery, from cachectic (CC = 25) or weight stable (WSC = 20) colon cancer patients, who signed the informed consent form, were submitted to morphological (light microscopy), immunological (immunohistochemistry and flow cytometry), and molecular (quantification of inflammatory factors by Luminex® xMAP) analyses.
resultsThere was no statistical difference in gender and age between groups. The content of plasma interleukin 6 (IL-6) and IL-8 was augmented in cachectic patients relative to those with stable weight (P = 0.047 and P = 0.009, respectively). The number of lymphocytic aggregates/field in the gut mucosa was higher in CC than in WSC (P = 0.019), in addition to those of the lamina propria (LP) eosinophils (P < 0.001) and fibroblasts (P < 0.001). The area occupied by goblet cells in the colon mucosa was decreased in CC (P = 0.016). The M1M2 macrophages percentage was increased in the colon of CC, in relation to WSC (P = 0.042). Protein expression of IL-7, IL-13, and transforming growth factor beta 3 in the colon was significantly increased in CC, compared with WSC (P = 0.02, P = 0.048, and P = 0.048, respectively), and a trend towards a higher content of granulocyte-colony stimulating factor in CC was also observed (P = 0.061). The results suggest an increased recruitment of immune cells to the colonic mucosa in CC, as compared with WSC, in a fashion that resembles repair response following injury, with higher tissue content of IL-13 and transforming growth factor beta 3.
conclusionsThe changes in the intestinal mucosa cellularity, along with modified cytokine expression in cachexia, indicate that gut barrier alterations are associated with the syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.